ClinicalTrials.gg
CompletedNCT06822283PlasMAUpdated Feb 12, 2025

Plasticity of Deep Brain Structures in Mild Cognitive Impairment and Healthy Aging

An interventional study of transcranial electric stimulation in Traumatic Brain Injury, sponsored by Friedhelm Hummel. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Friedhelm Hummel · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Sep 2021, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Brain Injuries, Traumatic with a site in Switzerland — 6 open to participants now, 8 under way, 2 of them phase 3. Brain Injuries, Traumatic · Switzerland.

Enrollment
16th of 23
19 · median 25
Started
2021
the only one that year
No phase
18 of 31
5 open now
Registered
26th of 31
by date
Lead sponsor
2 of 31
Friedhelm Hummel

Among the 31 studies in Brain Injuries, Traumatic with a site in Switzerland, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2021, is one of 18 with no phase, and was the 26th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

6 of the 31 studies in Brain Injuries, Traumatic with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Brain Injuries, Traumatic with a site in Switzerland, or all of them as a file.
02

Study summary

Acute and chronic cognitive impairment (TBI and MCI) is one of the most common problems in the growing and aging society of the 21st century. At an individual level, not all brain structures are affected with the same rate. There are subcortical structures less involved (e.g., the cerebellum), and other more involved (e.g., the hippocampus) in the cognitive decline with age or following a traumatism. To pave the way for personalized precision medicine in the field of cognitive preservation and recovery, there is a need for testing the impact of individually tailored innovative non-invasive neuro-technologies. In this project, we aim at testing the benefit of non-invasively stimulating subcortical structures to boost resilience in supporting motor and non-motor memory.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • non-invasive brain stimulation
  • deep brain stimulation
  • subcortical
  • memory
  • neuro-imaging
  • transcranial temporal interference stimulation
  • motor learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

TBI patients:

  • Age ≥ 18 years
  • Clinical diagnosis of TBI
  • No history of other severe neurological or psychiatric disorders

Exclusion criteria

Exclusion Criteria:

  • Unable to consent

    • Severe neuropsychiatric (e.g., major depression, severe dementia) or unstable systemic diseases (e.g., severe progressive and unstable cancer, life threatening infectious diseases)
    • Severe sensory or cognitive impairment or musculoskeletal dysfunctions prohibiting to understand instructions or to perform the experimental tasks
    • Inability to follow or non-compliance with the procedures of the study
    • for NIBS or MRI (1):

      • Electronic or ferromagnetic medical implants/device, non-MRI compatible metal implant
      • History of seizures
      • Medication that significantly interacts with NIBS being benzodiazepines, tricyclic antidepressants and antipsychotics
    • Regular use of narcotic drugs
    • Pregnancy
    • Request of not being informed in case of incidental findings
    • Concomitant participation in another trial involving probing of neuronal plasticity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Placebo comparator
    Placebo stimulation

    Sham stimulation : ramp-up \[5 s\] immediately followed by ramp-down \[5 s\] of high-frequency currents (see Vassiliadis et al., 2023, Nat Hum Behav for more details)

    Other: transcranial electric stimulation

  • Experimental
    Active stimulation

    Patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details

    Other: transcranial electric stimulation

Interventions

  • Othertranscranial electric stimulation

    tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.

06

What researchers measure

Primary outcomes

  1. Motor learning performance

    The primary outcome of the study is the amount of motor learning in a sequential finger-tapping task evaluated during and following training

    Time frame: From baseline to 24 hours after training

Secondary outcomes

  1. Brain connectivity

    Diffusion-weighted and resting-state MRI is performed at baseline and allows to evaluate inter-individual anatomical factors associated to the primary outcome

    Time frame: Baseline measure (before the intervention)

Other outcomes

  1. Demographic factors form

    These factors including age, sex, handedness, education level and profession, time of diagnosis, physical activity, independency and quality of life, medication, cognitive status will are used to evaluate responsiveness to the intervention

    Time frame: Baseline measure (before the intervention)

07

Study locations

2 sites
  • EPFL Valais, Clinique Romande de readaptation
    Sion, Valais 1951, Switzerland
  • EPFL, Campus Biotech
    Geneva, 1202, Switzerland
08

References and documents

Publications

  • Wessel MJ, Beanato E, Popa T, Windel F, Vassiliadis P, Menoud P, Beliaeva V, Violante IR, Abderrahmane H, Dzialecka P, Park CH, Maceira-Elvira P, Morishita T, Cassara AM, Steiner M, Grossman N, Neufeld E, Hummel FC. Noninvasive theta-burst stimulation of the human striatum enhances striatal activity and motor skill learning. Nat Neurosci. 2023 Nov;26(11):2005-2016. doi: 10.1038/s41593-023-01457-7. Epub 2023 Oct 19. PubMed 37857774 ↗
  • Vassiliadis P, Beanato E, Popa T, Windel F, Morishita T, Neufeld E, Duque J, Derosiere G, Wessel MJ, Hummel FC. Non-invasive stimulation of the human striatum disrupts reinforcement learning of motor skills. Nat Hum Behav. 2024 Aug;8(8):1581-1598. doi: 10.1038/s41562-024-01901-z. Epub 2024 May 29. PubMed 38811696 ↗
  • Vassiliadis P, Stiennon E, Windel F, Wessel MJ, Beanato E, Hummel FC. Safety, tolerability and blinding efficiency of non-invasive deep transcranial temporal interference stimulation: first experience from more than 250 sessions. J Neural Eng. 2024 Mar 11;21(2). doi: 10.1088/1741-2552/ad2d32. PubMed 38408385 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Feb 2024, 28 months.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's 28 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Feb 12, 2025
StartActual
Sep 15, 2021
Primary completionActual
Feb 2, 2024
CompletionActual
Feb 2, 2024
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06822283
Lead sponsor
Friedhelm Hummel
Collaborators
Clinique Romande de Readaptation, HUG University hospital, SNF Swiss National Foundation, The Novartis Foundation, Fondation Bertarelli, Wyss Center for Bio and Neuroengineering
Responsible party
Friedhelm Hummel (Prof. Dr. med., Ecole Polytechnique Fédérale de Lausanne) — Sponsor-investigator
First posted
Feb 12, 2025
Start date
Sep 15, 2021
Primary completion
Feb 2, 2024
Completion
Feb 2, 2024
Last update
Feb 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion